



# 5 soho Italy

SOCIETY OF HEMATOLOGIC ONCOLOGY

## 2023 ANNUAL CONFERENCE

### HYBRID EVENT

03 - 06 Oct 2023

A.Roma Lifestyle Hotel  
Rome, Italy



## PRESIDENTS

C. Cerchione, H. Kantarjian, G. Martinelli

## SCIENTIFIC BOARD

K.C. Anderson, C. Cerchione, N. Daver, A. De La Fuente, C. DiNardo, A. Ferrajoli, G. Garcia-Manero, E. Jabbour, N. Jain, H. Kantarjian, H.C. Lee, T. Kadia, M. Konopleva, G. Martinelli, G. Musuraca, A. Paulus, F. Ravandi, G. Saglio

## TOPICS

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma and MGUS, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, CAR-T and Cellular Therapy, Supportive care in hematological malignancies

JOIN Us  
Become a Member



Follow us  
#SOHOItaly



Organizing secretariat



www.proeventi.it  
info@proeventi.it





## Italian ECM Accreditation

The Conference has been accredited to the Italian Ministry of Health:

Event n. 390468

Provider n. 2773

ECM Credits n. 24.5 for:

Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse  
Training objective 3: Clinical documentation. Diagnostic and rehabilitation  
clinical-care pathways, care profiles - treatment profiles.

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.



## EBAH CME Accreditation

Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting is accredited by the EBAH system. Participants of this meeting will receive 24.5 Credits following the entire Conference.



# Patronage



ALLEANZA  
CONTRO  
IL CANCRO




EUROPEAN  
HEMATOLOGY  
ASSOCIATION



# In Association with



# Promoted by



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico



provider n. 2773



info@proeventi.it  
www.proeventi.it

# SUMMARY

---

<b>1</b>	PARTNERSHIPS
<b>3</b>	SUMMARY
<b>4</b>	ABOUT SOHO ITALY
<b>6</b>	PRESIDENTS
<b>7</b>	SCIENTIFIC BOARD
<b>11</b>	SCIENTIFIC SECRETARIAT
<b>12</b>	FACULTY
<b>18</b>	KEY INFORMATION
<b>19</b>	GENERAL INFORMATION
<b>20</b>	PUBLIC TRANSPORT
<b>22</b>	PROGRAM TABLE
<b>26</b>	TUESDAY, OCT. 03 <sup>RD</sup>
<b>31</b>	WEDNESDAY, OCT. 04 <sup>TH</sup>
<b>38</b>	THURSDAY, OCT. 05 <sup>TH</sup>
<b>43</b>	FRIDAY, OCT. 06 <sup>TH</sup>
<b>50</b>	SUPPORTERS



## **What is SOHO Italy?**

The Italian Society of Hematologic Oncology is bringing together leading SOHO experts and top Italian researchers in Acute Leukemias, Multiple Myeloma, Non-Hodgkin and Hodgkin Lymphomas, MPNs, MDS and rare diseases, and it aims to consolidate the Italian Hematology-SOHO partnership.

## **Purpose**

The aim of the association is the integration of the clinical-scientific activities of Italy and MD Anderson Cancer Center and the improvement of the clinical-therapeutic approach to patients with hematologic malignancies.

## **Represented by**

The society SOHO ITALY is represented by G. Martinelli and C. Cerchione (IRST IRCCS), H. Kantarjian, E. Jabbour N. Daver (MD Anderson Cancer Center) and M. Konopleva (Albert Einstein College of Medicine, New York)



# PRESIDENTS

## Claudio Cerchione



Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassador of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association (EHA).

## Hagop Kantarjian



Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003 - present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics.

## Giovanni Martinelli



As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology "L. & A. Seragnoli", Azienda Ospedaliera S. Orsola - Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute Leukemias, CML (both Philadelphia-chromosome positive and non - positive), and hypereosinophilic syndrome.





# SCIENTIFIC BOARD

Claudio Cerchione, Hagop Katarjian, Giovanni Martinelli

## Kenneth C. Anderson



Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

## Naval G. Daver



Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance.

## Adolfo De La Fuente



Dr Adolfo de la Fuente has specialized in Onco-Hematology diseases, he is currently working at MD Anderson CC Madrid as Head of the Hematology Department and responsible for the Onco-hematology clinical trials Unit.

Dr. de la Fuente is a member of the Spanish Society of Hematology (SEHH) and the European Hematology Association (EHA).

He also has an active role in Spanish national working groups PETHEMA on Acute and Chronic Leukemia. He has been involved in numerous clinical trials focused on Leukemia and Lymphoma and has led studies on this area in Spain.



## Courtney DiNardo



Dr. DiNardo interests are focused on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014. The HHMC provides research based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials.

## Alessandra Ferrajoli



Dr. Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields Dr. Ferrajoli has authored and co-authored more than two hundred and fifty publications in peer reviewed journals. She serves on numerous journal editorial boards and grant proposal study sessions for several US and European Agencies.

## Guillermo Garcia-Manero



Guillermo Garcia-Manero, M.D., is a physician-scientist specializing in state-of-the-art treatments for leukemia. His research focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and his goal is develop and validate new therapeutics to treat these deadly diseases. He leads teams of clinicians, medical fellows, nurses, physician assistants and researchers to conduct pre-clinical, translational, and clinical studies. The goal of these studies is to understand, treat, and eventually cure MDS, AML and other leukemias.



## Elias Jabbour



Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; 5) triple therapy in AML.

## Nitin Jain



Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He then moved to the United States and completed his Internal Medicine residency training at the Medical College of Wisconsin, Milwaukee, Wisconsin. He then completed a year of clinical fellowship in Leukemia at MD Anderson Cancer Center followed by another year of Leukemia research fellowship at the Memorial Sloan-Kettering Cancer Center in New York. He then pursued fellowship in Hematology/Oncology at the University of Chicago.

## Hans C. Lee



Hans C. Lee, MD, is an Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas where he focuses his efforts on the clinical care and research of patients with plasma cell dyscrasias. He has a particular interest and focus on early phase clinical trials and novel therapeutic approaches to relapsed and/or refractory multiple myeloma.



## Tapan M. Kadia



Dr. Tapan Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these.

## Marina Konopleva



Dr. Konopleva is a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. Her laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs.

## Gerardo Musuraca



Dr. Musuraca is the Chief of Hematology Unit at IRST – IRCCS, in Meldola (FC), Italy. After a degree cum laude at the University of Bologna and a specialization in Hematology, since January 2006 he has been a PhD student in Clinical and Experimental Hematology at the University of Bologna. In 2007 he began the Clinical activity and research at Cancer Institute of Romagna. He is also Abstracts Reviewer and moderator on lymphoma, preclinical and biological agents of the American Society of Hematology meeting (ASH) and in December 2011 he reached a highly specialized position on Lymphomas at the Cancer Institute of Romagna.



## Aneel Paulus



As a translational scientist, Aneel Paulus, M.D., conducts scientific investigations that seek to address the clinical challenges of patients with hematologic cancers. Because there is an incomplete molecular understanding of these challenges, Dr. Paulus centers his research on the biomolecular and immunologic mechanisms associated with drug resistance in B-cell cancers.

Dr. Paulus' team utilizes advanced computational, genomic and immunology-based techniques to study the effects of targeted-therapies on tumor-cell signaling pathways and how this influences their interaction with the innate and adaptive immune system.

## Farhad Ravandi-Kashani



Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.

## Giuseppe Saglio



Giuseppe Saglio is Full Professor of Internal Medicine and Hematology at the University of Turin. He graduated from the University of Turin in 1975. Since then he has studied Internal Medicine at the University of Turin (1975-1980), Hematology at the University of Milan (1980-1983), and Molecular Biology at the University of Leiden (1976), Inserm-Creteil, Paris (1979) and at the University of California (1983). Prof. Saglio is coordinator of the PhD program in Molecular Medicine at the University of Turin, past-president of the Italian Society of Experimental Hematology (SIES) and is a member of the Academy of Medicine of Turin.

# SCIENTIFIC SECRETARIAT

Claudio Cerchione, Giovanni Martinelli, Gerardo Musuraca



# FACULTY

Elisabetta **Abruzzese**

Sikander **Ailawadhi**

Kenneth C. **Anderson**

Micheal **Andreeff**

Niccolo' **Bolli**

Giuliano **Bolondi**

Cirino **Botta**

Benedetto **Bruno**

Gabriele **Buda**

Natalie S. **Callander**

Amanda **Cashen**

Claudio **Cerchione**

Asher **Chanan-Khan**

Daniela **Cilloni**

Simona **Colla**

Elena **Crisà**

Antonio **Cuneo**

Naval **Daver**

Matteo **Da Vià**

Adolfo **De La Fuente**

Carmino **De Souza**

Michel **Delforge**

Julio **Delgado**

Matteo **Della Porta**

Rome

Jacksonville

Boston

Houston

Milan

Reggio Emilia

Palermo

Turin

Pisa

Madison

Seattle

Meldola (FC)

Jacksonville

Turin

Houston

Turin

Ferrara

Houston

Milan

Madrid

Campinas

Leuven

Barcelona

Milan



Enrico <b>Derenzini</b>	Milan
Daniele <b>Derudas</b>	Cagliari
Courtney <b>DiNardo</b>	Houston
Konstanze <b>Doehner</b>	Ulm
Massimo <b>Dominici</b>	Modena
Jean <b>El Cheikh</b>	Beirut
Brunangelo <b>Falini</b>	Perugia
Alessandra <b>Ferrajoli</b>	Houston
Felicetto <b>Ferrara</b>	Naples
Andres <b>Ferreri</b>	Milan
Robin <b>Foà</b>	Rome
Sara <b>Fraticelli</b>	Pavia
Gianluca <b>Gaidano</b>	Novara
Sara <b>Galimberti</b>	Pisa
Carlo <b>Gambacorti-Passerini</b>	Milan
Guillermo <b>Garcia-Manero</b>	Houston
Irene <b>Ghobrial</b>	Boston
Domenico <b>Girelli</b>	Verona
Shakira Jeanene <b>Grant</b>	Chapel Hill
Birol <b>Guvenc</b>	Adana
Hamed <b>Hanan</b>	Cairo
Ilaria <b>Iacobucci</b>	Memphis
Lorenzo <b>Iovino</b>	Seattle
Ahmad <b>Ibrahim</b>	Beirut
Elias <b>Jabbour</b>	Houston
Nitin <b>Jain</b>	Houston



# FACULTY

Tapan **Kadia**

Hagop **Kantarijan**

Rami **Komrokji**

Marina **Konopleva**

Francesco **Lanza**

Hans **Lee**

Arcangelo **Liso**

Franco **Locatelli**

Alessandro **Lucchesi**

Stefano **Luminari**

Angelo **Maiolino**

Fabio **Malavasi**

Giovanni **Marconi**

Maria Paola **Martelli**

Giovanni **Martinelli**

Massimo **Massaia**

Maria Victoria **Mateos**

Massimiliano **Mazza**

Mauricette **Michallet**

Filippo **Milano**

Mohamad **Mohty**

Vittorio **Montefusco**

Philippe **Moreau**

Adrian **Mosquera**

Houston

Houston

Tampa

New York

Ravenna

Houston

Foggia

Rome

Meldola (FC)

Reggio Emilia

Rio de Janeiro

Turin

Meldola (FC)

Perugia

Meldola (FC)

Cuneo

Salamanca

Meldola

Lyon

Seattle

Paris

Milan

Nantes

Madrid





Tariq <b>Mughal</b>	Boston
Nikhil <b>Munshi</b>	Boston
Gerardo <b>Musuraca</b>	Meldola (FC)
Arnon <b>Nagler</b>	Tel Aviv
Ernesta Paola <b>Neri</b>	Calgary
Esther <b>Oliva</b>	Reggio Calabria
Attilio <b>Olivieri</b>	Ancona
Livio <b>Pagano</b>	Rome
Bruno <b>Paiva</b>	Salamanca
Aneel <b>Paulus</b>	Jacksonville
Naveen <b>Pemmaraju</b>	Houston
Antonello <b>Pinto</b>	Naples
Concetta <b>Quintarelli</b>	Rome
Farhad <b>Ravandi</b>	Houston
Karthik <b>Ramasamy</b>	Oxford
Roberto <b>Ria</b>	Bari
Jose Maria <b>Ribera</b>	Barcelona
Paul G. <b>Richardson</b>	Boston
Alessandra <b>Romano</b>	Catania
Marianna <b>Rossi</b>	Pavia
Gianantonio <b>Rosti</b>	Meldola (FC)
Giuseppe <b>Saglio</b>	Turin
Jesus <b>San-Miguel</b>	Navarra
Evangelos <b>Terpos</b>	Athens
Steve <b>Treon</b>	Boston
Calogero <b>Vetro</b>	Catania



Katja **Weisel**

Amer **Zeidan**

Hamburg

New Heaven

# ORAL COMMUNICATIONS FACULTY





# Key Information

## VENUE

A. ROMA LIFESTYLE HOTEL

Via Giorgio Zoega, 59, 00164 Roma, Italy

## MEETING

Tuesday, Oct. 03	12.00 - 19.30
Wednesday, Oct. 04	08.30 - 20.00
Thursday, Oct. 05	08.30 - 19.30
Friday, Oct. 06	08.30 - 19.00

## SOCIAL MEDIA

Soho Italy is active on various social media platform. Follow us on the networks below and get real-time updates:

## INTERNET

WiFi is available in all areas.





# General Information

## LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

## CLIMATE

The average temperature is around 16–27 degrees.

## BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

## HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

## TAXI

The single number to call a taxi is 060609

For other utilities on the taxi service, see [www.060608.it](http://www.060608.it)

The journey to/ from Fiumicino Airport: 48€

The journey to/ from Ciampino Airport: 30€

The rates from Termini railway station to the city centre should cost between € 8 - € 15.



# Public Transport



Termini railway station is 10 km from the hotel.

The hotel is connected to the center of Rome by tram line no. 8. The nearest tram stop can be reached on foot from the hotel and the tram will take you directly to Piazza Venezia in 15-20 minutes.

A.Roma Lifestyle Hotel also offers a shuttle service to and from the city center, available from 8.30 to 21.00. Reservation required.





# Program Table

Tuesday, Oct. 03

08.00

09.00

10.00

11.00

12.00

**ADAPTIVE Pre-Opening Lunch Symposium**

13.00

**Session 1: Opening Session**

14.00

**Session 2: Acute Lymphoblastic Leukemia - Clinical Session 1**

15.00

16.00

**Session 3: Acute Lymphoblastic Leukemia - Clinical Session 2**

17.00

18.00

**Session 4: Allogeneic stem cell transplantation in hematological malignancies: dead or alive and kicking?**

19.00

**Session 5: CAR-T in Hematological malignancies:  
from dream to reality**

20.00

21.00

**Sponsored Symposium by CURIS  
IRAK4 in Hematologic malignancies**

22





# Program Table

Wednesday, Oct. 04

07.00

08.00

**Breakfast with the Professors**

09.00

**Sponsored Symposium by MENARINI STEMLINE  
Tagraxofusp: a new innovative target therapy for BPDCN patients**

10.00

**Session 6: Acute Myeloid Leukemia – State of the art**

11.00

12.00

**Session 7: Acute Myeloid Leukemia – State of the art 2**

13.00

14.00

**Session 8: Acute Myeloid Leukemia – Clinical Session**

15.00

16.00

**Session 9: Acute Myeloid Leukemia – Clinical Session**

17.00

**Session 10: Myeloproliferative Neoplasms - State of the art**

18.00

19.00

**Session 11: Chronic Lymphocytic Leukemia**

20.00



# Program Table

Thursday, Oct. 05

07.00

08.00

09.00

**Breakfast with the Professors**

10.00

**FLT3 Inhibitors in Acute Leukemias**

11.00

**Session 12: Chronic Myeloid Leukemia – State of the art**

12.00

**Session 13: Myelodysplastic Syndromes - State of the art**

13.00

14.00

15.00

**Session 14: Non-Hodgkin and Hodgkin Lymphomas:  
State of the art**

16.00

17.00

**Session 14: Hodgkin Lymphomas: State of the art**

18.00

**Session 15: Spotlights on rare entities and non-malignant diseases**

19.00

20.00



# Program Table

Friday, Oct. 06

07.00

08.00

**Breakfast with the Professors**

09.00

**Sponsored Symposium ONCOPEPTIDES**

10.00

**Session 16: Multiple Myeloma - Biology**

11.00

**SOHO Italy – EHOc Joint Lecture**

12.00

**Session 17: Multiple Myeloma – Clinical Session 1**

13.00

14.00

**Session 18: Multiple Myeloma – Clinical Session 2**

15.00

**Session 19: Smoldering Myeloma**

16.00

**Session 20: Mayo Clinic - SOHO Italy Joint Symposium  
Open questions in Multiple Myeloma**

17.00

18.00

**Session 21: Multiple Myeloma – Clinical Session 3**

19.00

20.00



03  
10.23



**12.00 - 13.00 ADAPTIVE PRE-OPENING LUNCH SYMPOSIUM**

**Is it now the time to move MRD into clinical trials and into routine testing?**

**Chairs: C. Cerchione, E. Jabbour**

MRD preclinical data for ALL patients

**G. Martinelli**

MRD clinical data and cases for ALL patients

**E. Jabbour, N. Daver**

MRD preclinical data for MM patients

**K. Ramasamy**

MRD clinical data and cases for MM patients

**C. Cerchione**

**SESSION 1 • OPENING SESSION**

**Chairs: C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli**

**13:00 - 13:10 WELCOME AND INTRODUCTION**

**What is SOHO Italy and next steps**

C. Cerchione, H. Kantarjian, G. Martinelli

**SESSION 2 • ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL SESSION 1**

**Chairs: C. Cerchione, E. Jabbour, H. Kantarjian, G. Martinelli**

**13.30 - 13.45** How I manage Acute Lymphoblastic Leukemia at MDACC

**H. Kantarjian**

**13.45 - 14.00** How I manage Elderly Acute Lymphoblastic Leukemia at MDACC

**E. Jabbour**

**14.00 - 14.15** How I manage Acute Lymphoblastic Leukemia in Europe

**G. Martinelli**

**14.15 - 14.30** New insights in Acute Lymphoblastic Leukemia: Chemotherapy-free regimen in Ph-positive ALL

**E. Jabbour**



Tuesday, Oct. 03

**14.30 - 14.45** GIMEMA in Acute Lymphoblastic Leukemia: past, present and future

**R. Foà**

**14.45 - 14.55 Oral Communication 1 (ALL 1)**

**14.55 - 15.15 Discussion**

### **SESSION 3 • ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL SESSION 2**

**Chairs: D. Cilloni, E. Jabbour, N. Jain, M. Konopleva**

**15.15 - 15.30** How to better integrate monoclonal antibodies in the current therapy of Acute Lymphoblastic Leukemia patients

**D. Cilloni**

**15.30 - 15.45** New Cellular therapies in Adult Acute Lymphoblastic Leukemia: what's new?

**N. Jain**

**15.45 - 16.00** Ph-like Acute Lymphoblastic Leukemia

**M. Konopleva**

**16.00 - 16.15** CAR-T versus allogeneic stem cell transplantation in relapsed/refractory Acute Lymphoblastic Leukemia

**J. Ribera**

**16.15 - 16.30** The management of infectious complications during novel target therapies in Leukemia patients

**L. Pagano**

**16.30 - 16.40 Oral Communication 2 (ALL 2)**

**16.40 - 16.55: Discussion**

**16.55 - 17.15: Coffee Break**

**17.15 - 17.30: Special Lecture from SOHO MENA:**

How I manage Chronic Myeloid Leukemia at MDACC

**E. Jabbour**



## **SESSION 4 • ALLOGENIC STEM CELL TRANSPLANTATION IN HEMATOLOGICAL MALIGNANCIES: DEAD OR ALIVE AND KICKING?**

**Chairs: J. El Cheikh, M. Dominici, F. Milano, A. Nagler**

**17.30 - 17.45** New conditioning regimen pre-allogenic Stem cell transplantation

**J. El Cheikh**

**17.45 - 18.00** Which is the role of Allogenic Stem cell transplantation in the era of CAR-T?

**A. Nagler**

**18.00 - 18.15** How to develop a innovative cellular therapies center: from Clinical trials to real world data

**F. Milano**

**18.15 - 18.30 Discussion**

## **SESSION 5 • CAR-T IN HEMATOLOGICAL MALIGNANCIES: FROM DREAM TO REALITY**

**Chairs: G. Bolondi, J. Delgado, M. Dominici, F. Milano, A. Nagler**

**18.30 - 18.45** History of a success – First approved academic CAR-T in Europe

**J. Delgado**

**18.45 - 19.00** The role of translational researcher in CAR-T: toward academic CAR-T

**M. Mazza**

**19.00 - 19.15** How I overcome resistances in pediatric acute leukemias treated with new cellular therapies

**C. Quintarelli**



Tuesday, Oct. 03

**19.15 - 19.30** How I manage complications after CAR-T and bispecific antibodies: the point of view from reanimation room

**G. Bolondi**

**19.30 - 19.45** CAR-T in solid tumors – from research to clinical applications

**M. Dominici**

**19.45 Conclusions and closing remarks Day 1**

C. Cerchione, H. Kantarjian, G. Martinelli

**20.30 - 21.30 SPONSORED SYMPOSIUM BY CURIS**

**IRAK4 in Hematologic malignancies**

**Chairs: C. Cerchione, N. Daver, G. Garcia-Manero, G. Martinelli**

Spliceosome Mutations and the IRAK4 pathway

**G. Martinelli (12 min)**

FLT3 mutations and the IRAK4 pathway

**N. Daver (15 min)**

FLT3 mutations and the IRAK4 pathway

**G. Garcia-Manero (12 min)**

Clinical experience with IRAK4 Inhibition in Myelodysplastic Syndromes and Acute Leukemias

**G. Garcia-Manero (12 min)**

IRAK4 Inhibition in Myeloma and Lymphoma

**C. Cerchione (12 min)**

**Discussion and Conclusions**

C. Cerchione, N. Daver, G. Garcia-Manero, G. Martinelli



A hand is shown holding a glowing, ethereal energy field. The field is composed of intricate, web-like patterns in shades of blue and purple, with bright red and orange streaks and arcs. The background features a dark blue hexagonal grid pattern. The overall aesthetic is futuristic and high-tech.

04  
10.23



Wednesday, Oct. 04

**08.00 - 08.30 BREAKFAST WITH THE PROFESSORS**

**SPONSORED SYMPOSIUM BY MENARINI STEMLINE**

**Tagraxofusp: a new innovative target therapy for BPDCN patients**

**Chair: C. Cerchione**

**08.30 - 08.40** Introduction

**G. Martinelli**

**08.40 - 09.00** Characterization and diagnosis of BPDCN

**S. Fraticelli**

**09.00 - 09.20** Treatment and management of BPDCN: clinical data and long-term outcomes

**G. Marconi, M. Rossi**

**09.20 - 09.30 Discussion**

**G. Martinelli**

**SESSION 6 • ACUTE MYELOID LEUKEMIA - STATE OF THE ART**

**Chairs: N. Daver, C. DiNardo, T. Kadia, H. Kantarjian, G. Martinelli**

**09.30 - 09.45** Overview of new and revised European LeukemiaNet Working Party guidelines: Importance of molecular testing in Acute Myeloid Leukemia and practical considerations for clinical practice

**A. De La Fuente**

**09:45 - 10.00** How I manage Acute Myeloid Leukemia at MD Anderson Cancer Center

**H. Kantarjian**

**10.00 - 10.15** Non-Intensive Treatment of Elderly/Unfit Patients with Acute Myeloid Leukemia at MDACC

**T. Kadia**

**10.15 - 10.30** How I manage FLT3 mutated Acute Myeloid Leukemia: Moving Towards Cure

**G. Martinelli**



**10.30 - 10.45** How I manage IDH-mutated Acute Myeloid Leukemia at MDACC

**C. DiNardo**

**10.45 - 11.00** Immune and cellular approaches and role of Menin Inhibitors in Acute Myeloid Leukemia

**N. Daver**

**11.00 - 11.10** **Oral Communication 3 (AML 1)**

**11.10 - 11.20** **Discussion**

## **SESSION 7 • ACUTE MYELOID LEUKEMIA - STATE OF THE ART 2**

**Chairs: A. De La Fuente, K. Doehner, A. Olivieri, N. Pemmaraju**

**11.20 - 11.35** The role of molecular MRD monitoring in AML/NGS approaches

**K. Doehner**

**11.35 - 11.50** Current role of allogenic stem cell transplantation and Maintenance in Acute Myeloid Leukemia

**A. Olivieri**

**11.50 - 12.05** How I manage secondary Acute Myeloid Leukemia

**F. Lanza**

**12.05 - 12.20** **Special Lecture from SOHO France:**

New insights in Acute Myeloid Leukemia

**M. Michallet**

**12.20 - 12.30** **Discussion**

**12.30 - 13.30** **Lunch**



Wednesday, Oct. 04

## **SESSION 8 • ACUTE MYELOID LEUKEMIA - CLINICAL SESSION**

**Chairs: M. Andreef, B. Falini, M.P. Martelli, F. Ravandi**

**13.30 - 13.45** Targeted therapy of NPM1-mutated Acute Myeloid Leukemia - State of the art

**M.P. Martelli**

**13.45 - 14.00** Is All Oral Therapy of Acute Myeloid Leukemia a Reality for the Future?

**F. Ravandi**

**14.00 - 14.15** New strategies in induction of transplant-eligible Acute Myeloid Leukemia

**G. Marconi**

**14.15 - 14.30** TP53 in Myeloid Leukemias: Targeting the Guardian of the Genome

**M. Andreeff**

**14.30 - 14.45** **Oral Communication 4 (AML 2)**

**14.45 - 14.55** **Discussion**

## **SESSION 9 • ACUTE MYELOID LEUKEMIA - CLINICAL SESSION**

**Chairs: L. Brunetti, F. Ferrara, S. Galimberti, I. Iacobucci, A. Zeidan**

**14.55 - 15.05** Role of Immune Checkpoint Inhibitors in Acute Myeloid Leukemia

**A. Zeidan**

**15.05 - 15.20** NPM1 mutated AML: from bench to bedside

**L. Brunetti**

**15.20 - 15.35** The pathogenesis of acute leukemias: approaches and molecular insights

**I. Iacobucci**

**15.35 - 15.50** Digital droplet PCR in Hematologic malignancies: a new useful molecular tool

**S. Galimberti**



**15.50 - 16.00 Oral Communication 5 (AML 3)**

**16.00 - 16.10 Discussion**

**SESSION 10 • MYELOPROLIFERATIVE NEOPLASMS - STATE OF THE ART**

**Chairs: A. Liso, A. Lucchesi, T. Mughal**

**16.10 – 16.25** New insights in hemoglobinopathies and iron deficiency anemia

**D. Girelli**

**16.25 - 16.55 Importance of correct diagnosis in Myeloproliferative Neoplasms**

- Updates on WHO Classification of Myeloproliferative Neoplasms

**H. Hamed**

- From correct diagnosis to personalized medicine for Myeloproliferative Neoplasms

**T. Mughal**

**16.55 - 17.10** A new pathogenetic paradigm for Myeloproliferative Neoplasms: the “circulating wound”

**A. Lucchesi**

**17.10 - 17.25** Pregnancies in Myeloproliferative Neoplasms: how to manage these patients

**E. Abruzzese**

**17.25 - 17.35 Oral Communication 6 (MPN 1)**

**17.35 - 17.45 Discussion**



Wednesday, Oct. 04

## **SESSION 11 • CHRONIC LYMPHOCYTIC LEUKEMIA**

**Chairs: A. Cuneo, A. Ferrajoli, G. Gaidano, M. Massaia**

**17.45 - 18.00** How I manage Chronic Lymphocytic Leukemia at MDACC

**A. Ferrajoli**

**18.00 - 18.15** How I manage Chronic Lymphocytic Leukemia in Italy

**A. Cuneo**

**18.15 - 18.30** Role of monitoring and MRD in Chronic Lymphocytic Leukemia: when and why?

**M. Massaia**

**18.30 - 18.45** Which current sequencing in chronic lymphocytic leukemia's real world? -

**G. Gaidano**

**18.45 - 19.00** How to improve the use novel agents in elderly CLL

**A. Ibrahim**

**19.00 - 19.15** CAR T-cell therapy for Chronic Lymphocytic Leukemia: a new addition to our treatment toolbox?

**L. Iovino**

**19.15 - 19.25 Discussion**

**19.25 Conclusions and closing remarks Day 2**

C. Cerchione, H. Kantarjian, G. Martinelli

**Authorities' talks:**

**20.00 - 20.10** SOHO USA - Introduction of SOHO USA and its role

**N. Daver, E. Jabbour, H. Kantarjian**

**20.10 - 20.20** IRST - Introduction of IRST and its role

**R. Maffioli, F. Miserocchi, M.T. Montella**

**20.20 - 20.30** EHA Introduction of EHA and its role

**K. Doehner**



**20.30 - 20.40** COSTEM - Introduction of COSTEM and its role

**A. Nagler**

**20.40 - 20.50** AIOM -Introduction of AIOM and its role

**S. Cinieri**

**20.50 - 21.00** SOHO France - Introduction of SOHO France and its role


**M. Michallet**

**21.00 - 21.10** SOHO MENA - Introduction of SOHO USA and its role

**A. Ibrahim, E. Jabbour**

**21.10 - 21.20** EHOQ/SOHO Turkey - Introduction of SOHO Turkey and its role

**B. Güvenç, G. Saglio**



05  
10.23





**08.30 - 09.00 BREAKFAST WITH THE PROFESSORS**

**09.00 - 10.00 FLT3 INHIBITORS IN ACUTE LEUKEMIAS**

Chair: G. Martinelli

**09.00 - 09.15** The diagnostic of FLT3: present and future

**G. Marconi**

**09.15 - 09.30** How I treat FLT3 positive leukemias

**G. Martinelli**

**09.30 - 09.45** Efficacy and new insight in hematological malignancies FLT3 positive with FLT3 inhibitors

**G. Martinelli**

**09.45 - 09.55 Discussion**

**09.55 - 10.15 Coffee Break**

**SESSION 12 • CHRONIC MYELOID LEUKEMIA – STATE OF THE ART**

Chairs: C. Gambacorti-Passerini, G. Martinelli

**10.15 - 10.40** The transition from interferon to TKI therapy

**C. Gambacorti-Passerini**

**10.40 - 10.55** Treatment-free remission - State of the art

**G. Rosti**

**10.55 - 11.05 Oral Communication 8 (CML 1)**

**11.05 - 11.20 Discussion**



Thursday, Oct. 05

**SESSION 13 • MYELODYSPLASTIC SYNDROMES - STATE OF THE ART**  
**Chairs: S. Colla, M. Dalla Porta, G. Garcia Manero, R. Komrokji, E. Oliva**

**11.20 - 11.35** Updates and new insights in the biology of Myelodysplastic Syndromes

**S. Colla**

**11.35 - 11.50** Updates on classification and risk stratification for MDS

**R. Komrokji**

**11.50 - 12.05** A Practical Approach to Molecular Pathology of Myelodysplastic Syndromes

**M. Della Porta**

**12.05 - 12.20** Treatment of Lower Risk Myelodysplastic Syndromes

**E. Oliva**

**12.20 - 12.35** Management of High-Risk Myelodysplastic Syndromes in MDACC: a total approach

**G. Garcia-Manero**

**12.35 - 12.50** Target-therapies in Myelodysplastic syndromes: where are we going

**E. Crisà**

**12.50 - 13.00 Oral Communication 8 (MDS 1)**

**13.00 - 13.10 Discussion**

**13.10 - 14.20 Lunch**



**SESSION 14 • NON-HODGKIN AND HODGKIN LYMPHOMAS: STATE OF THE ART**

**Chairs: E. Derenzini, A. Ferreri, A. Mosquera, S. Luminari, G. Musuraca**

**14.20 - 14.35** How I manage Diffuse Large B-Cell Lymphoma in Europe  
**G. Musuraca**

**14.35 - 14.50** How I manage Follicular, marginal zone and mantle cell Lymphoma  
**S. Luminari**

**14.50 - 15.05** How to integrate the new diagnostic tools in the current daily management of Non Hodgkin Lymphomas  
**E. Derenzini**

**15.05 - 15.20** How I manage CNS lymphomas  
**A. Ferreri**

**15.20 - 15.35** New scores in NHL using genomics and machine learning: from prognostication to optimal treatment selection  
**A. Mosquera**

**15.35 - 15.45** Oral

**15.45 - 15.55** Discussion

**15.55 - 16.10** Coffee Break



Thursday, Oct. 05

## **SESSION 14 • HODGKIN LYMPHOMAS: STATE OF THE ART**

**Chairs: A. Cashen, E. Derenzini, C. De Souza, A. Ferreri, G. Musuraca**

**16.10 - 16.25** How I manage Hodgkin in Disease in USA

**A. Cashen**

**16.25 - 16.40** How I manage high stage newly diagnosed Hodgkin Lymphoma: toward a new standard of care?

**C. De Souza**

**16.40 - 16.50 Oral Communication 9 (NHL 1)**

**16.50 - 17.00 Discussion**

## **SESSION 15 • SPOTLIGHTS ON RARE ENTITIES AND NON-MALIGNANT DISEASES**

**Chairs: H.C. Lee, A. Romano, S. Treon, C. Vetro**

**17.00 - 17.15** How I manage Waldenstrom's Macroglobulinemia in the era of novel agents

**S. Treon**

**17.15 - 17.30** How I manage AL Amyloidosis at MDACC

**H.C. Lee**

**17.30 - 17.45** How I manage advanced systemic mastocytosis

**A. Romano**

**17.45 - 17.55 Oral Communication 10 (HL 1)**

**17.55 - 18.00 Discussion**

**18.00 Conclusions and closing remarks Day 3**

C. Cerchione, H. Kantarjian, G. Martinelli



06  
10.23



Friday, Oct. 06

**08.00 - 08.30 BREAKFAST WITH THE PROFESSORS**

**08.30 - 09.15 SPONSORED SYMPOSIUM ONCOPEPTIDES**

**The role of melphalan flufenamide in the Triple Class Refractory (TcR) MM patients**

**Chair: C. Cerchione**

Melphalan flufenamide mechanism of action in TcR: present and future synergisms

**E. Terpos**

Current Clinical Positioning of melphalan flufenamide

**C. Cerchione**

How to treat elderly patients: the role of melphalan flufenamide

**V. Montefusco**

How to treat difficult patients and/or heavily pre-treated Patients (EMD, renal failure..)

**K. Weisel**

**Discussion and closing remarks**

C. Cerchione

**SESSION 16 • MULTIPLE MYELOMA - BIOLOGY**

**Chairs: N. Bolli, E.P. Neri, B. Paiva, A. Vacca**

**09.15 - 09.30** How and when to integrate flow cytometry in daily practice of Multiple Myeloma

**B. Paiva**

**09.30 - 09.45** Genomics of Smoldering Multiple Myeloma: from basic science to clinical applications

**M.C. Da Vià**

**09.45 - 10.00** Determinants of Resistance to CAR-T and T-cell Engagers in Multiple Myeloma

**E.P. Neri**



**10.00 - 10.15** Targeting the bone marrow microenvironment in Multiple Myeloma

**C. Botta**

**10.15 - 10.30** New insights in anti-angiogenesis in Multiple Myeloma

**R. Ria and G. A. Solimando**

**10.30 - 10.40 Oral Communication 12 (MM 1)**

**10.40 - 10.50 Discussion**

**10.50 - 11.15 Coffee Break**

### **SOHO ITALY – SOHO TURKEY/EHOG JOINT LECTURE**

**Chairs: C. Cerchione, D. Cilloni, B. Güvenç, G. Martinelli, G. Saglio**

**11.15 – 11.30** What is EHOG/SOHO Turkey and New insights from EHOG-SOHO Turkey

**B. Güvenç, G. Saglio**

### **SESSION 17 • MULTIPLE MYELOMA – CLINICAL SESSION 1**

**Chairs: K.C. Anderson, C. Cerchione, H.C. Lee, M.V. Mateos, P. Moreau**

**11.30 - 11.45** Multiple Myeloma: State of the art in Europe

**C. Cerchione**

**11.45 - 12.00** Multiple Myeloma: State of the art in USA

**H.C. Lee**

**12.00 - 12.15** Multiple myeloma cured in 2030: what are the next steps?

**K.C. Anderson**

**12.15 - 12.30 Special Lecture - EHA-ESMO**

Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up in Multiple Myeloma: what is changing?

**P. Moreau**



Friday, Oct. 06

**12.30 - 12.45 Discussion**

**12.45 - 13.30 Lunch**

**SESSION 18 • MULTIPLE MYELOMA – CLINICAL SESSION 2**

**Chairs: C. Cerchione, A. Maiolino, V. Montefusco, P. Richardson, J. San-Miguel**

**13.30 - 13.45** How I manage Transplant Multiple Myeloma in frontline setting  
**V. Montefusco**

**13.45 - 14.00** Is anti-CD38-based induction therapy for every patient?  
**P. Richardson**

**14.00 - 14.30** New insights and opportunities for Lenalidomide - refractory patients

**CAR-T**  
**J. San-Miguel**      versus      **STANDARD OF CARE**  
**A. Maiolino**

**14.30 – 14.40 Discussion**

**SESSION 19 • SMOLDERING MYELOMA**

**Chairs: N. Callander, C. Cerchione, I. Ghobrial, M.V. Mateos, P. Richardson**

**14.40 - 14.55** Is it time for biomarkers-driven approach in Smoldering Myeloma and Multiple Myeloma?  
**I. Ghobrial**

**14.55 - 15.10** How I manage Smoldering Multiple Myeloma In Europe  
**M.V. Mateos**

**15.10 - 15.25** How I manage Smoldering Multiple Myeloma in USA  
**N. Callander**

**15.25 - 15.35 Oral Communication 12 (MM 2)**

**15.35 - 15.45 Discussion**





## **SESSION 20 • MAYO CLINIC - SOHO ITALY JOINT SYMPOSIUM - OPEN QUESTIONS IN MULTIPLE MYELOMA**

**Chairs: S. Ailawadhi, B. Bruno, C. Cerchione, A.A. Chanan-Khan, F. Malavasi, A. Paulus, M. Mohty**

**15.45 - 16.00** CD38: reflecting on the past to move to the future  
**F. Malavasi**

**16.00 - 16.15** Time for new targets: Bench-to-Bedside Development of Bcl-2 inhibitors for Treatment of Multiple Myeloma and lymphoproliferative disorders  
**A. Paulus**

**16.15 - 16.30** How to integrate bispecific antibodies in current therapeutic scenario of Multiple Myeloma  
**S. Ailawadhi**

**16.30 - 17.00** CAR-T in 2023 in Multiple Myeloma: Have We the promised land?  
**In Europe - B. Bruno**  
**In USA - A.A. Chanan-Khan**

**17.00 -17.15** Will autologous Stem cell transplantation be replaced by CAR-T in Multiple Myeloma?  
**M. Mohty**

**17.15 - 17.25 Discussion**

## **SESSION 21 • MULTIPLE MYELOMA – CLINICAL SESSION 3**

**Chairs: G. Buda, S.J. Grant, NC Munshi, A. Romano, E. Terpos**

**17.25 - 17.40** How I manage elderly and unfit patients  
**G. Buda**

**17.40 - 17.55** How I manage bone disease and its complications in Multiple Myeloma  
**E. Terpos**

**17.55 - 18.05** Which is the correct sequencing of novel agents and combinations in relapsed/refractory Multiple Myeloma  
**A. Romano**



Friday, Oct. 06

**18.05 - 18.20** How I manage extramedullary disease and plasma cell leukemia

**D. Derudas**

**18.20 - 18.35** Health-related quality of life in relapsed and refractory multiple myeloma

**M. Delforge**

**18.35 - 18.55** Merging Molecular and Aging Assessments to Guide Therapy in Older Patients With Myeloma

**S. J. Grant**

**18.55 - 19.05** Life after CAR-T and bispecific: from trials to real world

**N.C. Munshi**

**19.05 - 19.15 Discussion**

**19.15 Prizes and Conclusions. See you next year**

C. Cerchione, H. Kantarjian, G. Martinelli

A photograph of the dome of St. Peter's Basilica in Rome, Italy, taken at sunset. The dome is the central focus, with its intricate architectural details and the lantern on top. The sky is a warm, golden-orange color, and the surrounding cityscape is visible in the background. The text "SEE YOU NEXT YEAR!" is overlaid in large, white, bold, sans-serif font in the upper right quadrant.

SEE YOU  
NEXT  
YEAR!



**SUPPORTED BY  
AN UNRESTRICTED  
EDUCATIONAL  
GRANT  
FROM**



## DIAMOND

**Stemline**<sup>®</sup>

A Menarini Group Company

## PLATINUM

abbvie

## GOLD

**Adaptive**  
biotechnologies™

CURIS<sup>®</sup>

## SILVER

 **astellas**  
for virtual platform

 **BeiGene**

  
Daiichi-Sankyo

 **oncopeptides**

## BRONZE

 **ARROW**  
DIAGNOSTICS

 **AstraZeneca**

 **blueprint**  
MEDICINES

**immun•gen**

 **janssen Oncology**  
PHARMACEUTICAL COMPANY OF Johnson & Johnson

 **MASSIVEBIO**

 **Pfizer**

 **Protagonist**  
Therapeutics

 **prothena**

**sanofi** **werfen**



## Follow Us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOItaly

You can use it on Facebook, Twitter, Instagram, Youtube and LinkedIn.

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly

@SocietyofHemOnc

@IRSTufficiale

@MDAndersonNews

@pro\_eventi

@GMartinelli2

@DottorClaudio

@DrHKantarjian

**Enjoy & Share your experience!**

Follow us





## Media Partners

**PHARMASTAR**<sup>★</sup>  
il Giornale online sui Farmaci

**VJHEMONC**  
The Video Journal of Hematological Oncology

**VUMEDI**



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI